Verve Therapeutics

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve's mission is to create a new generation of gene therapies for the prevention and treatment of cardiovascular disease by targeting genetic mutations and leveraging the latest advances in precision medicine.

Verve's vision is to become the leader in cardiovascular gene therapy and to help people live longer, healthier lives by restoring cardiovascular health.

Verve Therapeutics has been recognized as one of the World Premier Innovation Award winners in the Technology & Innovation Strategy category by the U.S. National Academy of Engineering. Additionally, Verve Therapeutics was named one of the MIT Technology Review’s “50 Smartest Companies” in 2019.